The state-of-the-art research and development center in Georgia will help improve the health and wellbeing of animals ...

Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the oncology-focused platform company’s decision to file for bankruptcy. Notable's ...

The $66 million project is part of the company's obligation made to the state after it moved here to invest a total of $120 ...

The Gainesville Dining Services focus on the recipe for your satisfaction by serving up quality, convenience, value, and healthy options across our several retail locations. Gainesville Dining ...

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

With a capital investment of US$66.1 million and 63 new jobs created, this expansion includes the addition of 63,000 square feet of administrative space and more than 28,000 square feet of laboratory ...

Best Cheap Car Insurance Companies in Gainesville, Ga. How Much Is Car Insurance in Gainesville, Ga.? Gainesville Car Insurance Quotes by Driver Profile Cheap Car Insurance in Gainesville ...

The heritage of Boehringer Ingelheim in developing medicines for respiratory diseases spans almost 100 years. Within the respiratory disease area, innovative treatments for chronic obstructive ...

Boehringer Ingelheim has taken an option on a family of compounds with potential as therapies for schizophrenia from Sosei Heptares, which it says could have broad activity against the symptoms of ...

She's currently the Chief Medical Officer and Head of Medicine at Boehringer Ingelheim. Well, Dr. Hinsch Gylvin. Thanks for joining me today. That really has changed. So first and foremost ...

Boehringer Ingelheim is supporting this transformation by partnering with groups working across psychiatric R&D, from small molecules to digital therapeutics. Recognizing the potential to improve ...

Abdulla also aims to further strengthen relationships with regional governments and key healthcare stakeholders to ensure sustainable patient access to Boehringer Ingelheim’s portfolio of leading ...